Showing 40,041 - 40,060 results of 82,755 for search '(( a d decrease ) OR ( 50 ((we decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.56s Refine Results
  1. 40041

    Table_3_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx by Haiyan Zeng (3753130)

    Published 2022
    “…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
  2. 40042

    Table_4_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx by Haiyan Zeng (3753130)

    Published 2022
    “…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
  3. 40043

    Table_6_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx by Haiyan Zeng (3753130)

    Published 2022
    “…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
  4. 40044

    Table_2_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx by Haiyan Zeng (3753130)

    Published 2022
    “…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
  5. 40045

    Table_7_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx by Haiyan Zeng (3753130)

    Published 2022
    “…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
  6. 40046

    Table_1_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx by Haiyan Zeng (3753130)

    Published 2022
    “…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
  7. 40047

    Table_5_Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.docx by Haiyan Zeng (3753130)

    Published 2022
    “…Eligibility criteria: studies reporting detailed BM data with an adequate sample size (randomized clinical trials [RCTs]: N ≥50; non-RCTs: N ≥100) in patients with SCLC. We summarized the reported risk factors and performed meta-analysis to estimate the pooled hazard ratios (HR) if enough qualified data (i.e., two or more studies; the same study type; the same analysis method; and HRs retrievable) were available. …”
  8. 40048
  9. 40049
  10. 40050

    Data_Sheet_1_A Novel Canine Mammary Cancer Cell Line: Preliminary Identification and Utilization for Drug Screening Studies.docx by Rifei Li (10883826)

    Published 2021
    “…The successfully established cell line, B-CMT, was cultured over 50 passages. B-CMT has a fast proliferation rate, and a population doubling time (PDT) of 33.6 h. …”
  11. 40051

    Table_1_A Case–Control Study of ADCY9 Gene Polymorphisms and the Risk of Hepatocellular Carcinoma in the Chinese Han Population.DOCX by Xu Chao (303855)

    Published 2020
    “…In addition, haplotype analysis indicated that C<sub>rs879620</sub>A<sub>rs2230742</sub>A<sub>rs2230741</sub> haplotype was a protective factor for HCC (OR = 0.67, 95% CI = 0.50–0.89, p = 0.007, FDR-p = 0.028).…”
  12. 40052
  13. 40053
  14. 40054
  15. 40055
  16. 40056

    Table_1_Association between handgrip strength asymmetry and cognitive function across ethnicity in rural China: a cross-sectional study.DOCX by Wenjing Feng (476896)

    Published 2023
    “…Generalized linear models were used to analyze the relationship between asymmetric HGS and cognitive function adjusted for HGS, handedness, wave, age, sex, education, ethnicity, smoking, drinking, physical labor level, BMI, hypertension, diabetes and dyslipidemia.</p>Result<p>A total of 2,969 participants ≥50 years were included in this study. …”
  17. 40057
  18. 40058

    DataSheet_1_A Pathogenic Missense Variant in NFKB1 Causes Common Variable Immunodeficiency Due to Detrimental Protein Damage.pdf by Manfred Fliegauf (391677)

    Published 2021
    “…In four affected members of a German family, all diagnosed with CVID, we identified a previously uncharacterized heterozygous NFKB1 missense variant (c.1049A>G; p.Tyr350Cys). …”
  19. 40059

    DataSheet_1_A Pathogenic Missense Variant in NFKB1 Causes Common Variable Immunodeficiency Due to Detrimental Protein Damage.pdf by Manfred Fliegauf (391677)

    Published 2021
    “…In four affected members of a German family, all diagnosed with CVID, we identified a previously uncharacterized heterozygous NFKB1 missense variant (c.1049A>G; p.Tyr350Cys). …”
  20. 40060